Glycaemic impact of treatment intensification in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs or basal insulin

@inproceedings{Buysman2018GlycaemicIO,
  title={Glycaemic impact of treatment intensification in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs or basal insulin},
  author={Erin K Buysman and Tao Fan and Cori Blauer-Peterson and Lesley-Ann Miller-Wilson},
  booktitle={Endocrinology, diabetes & metabolism},
  year={2018}
}
  • Erin K Buysman, Tao Fan, +1 author Lesley-Ann Miller-Wilson
  • Published in
    Endocrinology, diabetes…
    2018
  • Medicine
  • Aims To investigate the impact of treatment intensification (TI) on glycaemic outcomes in patients with type 2 diabetes with glycated haemoglobin A1c (A1C) ≥7% after ≥6 months of treatment with 2 oral antidiabetes drugs (OADs) or basal insulin (BI). Materials and Methods Data were extracted from the Optum administrative claims database from 1 January 2009 to 31 August 2015. Patients with TI ≤6 months after the first A1C ≥7% (index date) were compared with patients with no TI (NTI). TI… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 33 REFERENCES

    Agency for Healthcare Research and Quality. Clinical Classifications Software (CCS) for ICD-9-CM (software)

    • BUYSMAN
    • https://www. hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp. Accessed February
    • 2018

    Factors associated with nonintensification of insulin therapy among patients with type 2

    • SD Hopson, F Ye, +3 authors AM Renda
    • diabetes
    • 2017

    Factors associated with nonintensification of insulin therapy among patients with type 2 diabetes

    • SD Hopson, F Ye, +3 authors AM. Renda
    • Diabetes. 2017;66(Suppl. 1):A449
    • 2017

    Adding Rapid-Acting Insulin or GLP-1 Receptor Agonist to Basal Insulin: Outcomes in a Community Setting.